Revenue segments as reported by the company.

Instruments & Accessories

Systems

Services

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Intuitive Surgical

Intuitive Surgical, Inc. engages in the development, manufacture, and marketing of da Vinci Surgical Systems, and related instruments and accessories for invasive surgery. Its products include Da Vinci and Ion. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Earnings data Q2 2026

Intuitive Surgical excels in Q2 performance, eyes AI opportunities

Intuitive Surgical's Q2 2023 performance showcased strong revenue growth, procedure increases, and a focus on healthcare improvement.
The company's strengths include innovative ecosystem investments, commitment to patient outcomes, and advanced surgical technologies.
Challenges include market disruptions from new drugs, expense management, and adapting to changing healthcare landscapes.
Opportunities in AI, market expansion, and new procedures position Intuitive Surgical for continued growth and innovation.

Intuitive Surgical excels in Q3, eyes global expansion and margin growth

Intuitive Surgical's Q3 performance reflects strong growth and strategic focus on innovation and market expansion. Despite challenges in specific procedure categories and pricing dynamics, the company is well-positioned to capitalize on opportunities for growth and margin improvement.

Intuitive Surgical posts strong 2023 results, da Vinci 5 launch ahead

Intuitive Surgical's 2023 performance reflects strong revenue growth, operational excellence, and a strategic focus on innovation with the upcoming da Vinci 5 launch.
While facing challenges in operating margin pressure and supply chain issues, the company is well-positioned to capitalize on opportunities in soft tissue surgery, big data integration, and leased placements.
Investors should monitor how Intuitive Surgical navigates the launch of da Vinci 5, manages operational challenges, and leverages growth opportunities to sustain its market leadership.
Overall, Intuitive Surgical's Q4 earnings call highlights a resilient business model, customer-centric approach, and a commitment to advancing surgical technology for better patient outcomes.

Intuitive Surgical posts robust Q1 results amidst global market challenges

Intuitive Surgical delivered strong Q1 results with notable procedure and revenue growth, despite challenges in certain markets.
The company's focus on newer platforms, operational efficiency, and strategic outlook for 2024 positions it for continued success.
Addressing challenges and seizing opportunities in global markets and product innovation will be key for sustained growth and competitiveness.

Intuitive Surgical excels in Q2, eyes global expansion and innovation

Intuitive Surgical's Q2 performance reflects strength in procedure growth and system platform advancements.
The company's commitment to innovation and value creation positions them well for future success.
Challenges include sustaining margins and navigating market dynamics, while opportunities lie in expansion and innovation.
Overall, Intuitive Surgical's focus on growth, technology, and patient care sets a positive trajectory for the future.

Intuitive Surgical excels in Q3 with strong growth and innovation

Intuitive Surgical's Q3 2024 performance reflects a company in a strong position with notable achievements in procedures, financials, and technological advancements. While facing challenges in margin progression and international expansion, the company is well-positioned to leverage opportunities in innovation and customer insights.

Intuitive Surgical posts robust Q4 results, eyes innovation for growth

Intuitive Surgical (ISRG) delivered a strong performance in Q4 2024, marked by financial growth, procedure adoption, and system utilization.
The company's strategic focus on innovation, product expansion, and addressing competition positions them well for future growth and market leadership.
While challenges in sustaining growth and managing expenses exist, opportunities in new product launches, market expansion, and improved patient outcomes are on the horizon.

Intuitive Surgical excels in Q1 2025, updates forecasts amidst challenges

Intuitive Surgical's Q1 2025 performance showcased strength in procedure growth, revenue, and profitability, driven by robust da Vinci system placements. While facing challenges from increased expenses and global tariffs, the company remains optimistic about growth opportunities and operational efficiency. With an updated forecast for procedure growth and gross margin, Intuitive Surgical is poised to navigate challenges and leverage opportunities for sustained success. Investors can find confidence in the company's solid financial performance, strategic updates, and commitment to innovation and market leadership.

Intuitive Surgical posts stellar Q2 results, eyes global expansion and innovation

Intuitive Surgical's Q2 2025 performance reflects strong financial metrics, robust da Vinci system placements, and strategic growth initiatives. While facing challenges such as rising operating expenses and tariff impacts, the company remains focused on innovation and global expansion. Opportunities lie in market diversification, product innovation, and proactive adaptation to regulatory changes for sustained long-term success. Investors can be optimistic about ISRG's solid performance, growth prospects, and commitment to advancing surgical technology and patient care.

Intuitive Surgical excels in Q3 with strong revenue and procedure growth

Intuitive Surgical's Q3 2025 performance reflects strong demand for its robotic surgery systems, leading to impressive revenue and earnings growth. The company's focus on innovation, customer engagement, and market expansion positions it well for future success.

Intuitive Surgical posts record revenue growth and plans global expansion

Intuitive Surgical delivered strong financial results in Q4 2025, driven by revenue growth and increased da Vinci system placements. The company's focus on innovation, global expansion, and improving patient outcomes positions it well for future growth. While facing challenges in managing expenses and market competition, Intuitive Surgical has opportunities to capitalize on its strengths and expand its market presence.

Intuitive Surgical reports robust Q1 performance and strategic growth outlook

Intuitive Surgical's Q1 2026 earnings call highlighted strong procedure growth, revenue increase, and operational efficiency. Despite challenges in Asia, the company is focused on international strategy enhancements and product innovation to drive future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.